Is ANI Pharmaceuticals, Inc. (ANIP) a Buy? The Stock Rises Again

Investors sentiment increased to 1.96 in 2019 Q2. Its up 0.16, from 1.8 in 2019Q1. It improved, as 8 investors sold ANI Pharmaceuticals, Inc. shares while 41 reduced holdings. 29 funds opened positions while 67 raised stakes. 8.26 million shares or 10.11% more from 7.50 million shares in 2019Q1 were reported.
Hussman Strategic Advsr holds 25,000 shares or 0.57% of its portfolio. North Carolina-based Wedge Cap Management L Ltd Partnership Nc has invested 0.01% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Mark Sheptoff Planning Ltd Liability holds 3,750 shares. Dimensional Fund Advsrs Lp holds 537,427 shares or 0.02% of its portfolio. Gsa Cap Prtn Limited Liability Partnership invested in 25,148 shares. Smith Asset Management Gru Limited Partnership reported 5,660 shares. Nelson Van Denburg Campbell Wealth Mgmt Gru Lc holds 765 shares or 0.01% of its portfolio. Rafferty Asset Management Limited Company holds 0.02% or 10,614 shares. Charles Schwab Inv Mgmt has invested 0.01% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Sei Invs reported 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Clearbridge Investments Limited Liability Co invested in 25 shares. The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Thb Asset Mgmt holds 89,305 shares. Tci Wealth Advisors Inc invested 0% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Regent Mngmt Limited Liability holds 1.04% or 39,009 shares.

Since May 15, 2019, it had 1 buying transaction, and 2 sales for $4.76 million activity. $173,240 worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was bought by HAUGHEY THOMAS.

The stock of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a huge mover today! The stock increased 6.64% or $4.81 during the last trading session, reaching $77.29. About 236,562 shares traded or 44.95% up from the average. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has risen 25.49% since September 13, 2018 and is uptrending. It has outperformed by 25.49% the S&P500.
The move comes after 5 months positive chart setup for the $934.99M company. It was reported on Sep, 13 by We have $80.38 PT which if reached, will make NASDAQ:ANIP worth $37.40 million more.

Analysts await ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to report earnings on November, 5. They expect $1.32 EPS, up 12.82 % or $0.15 from last year’s $1.17 per share. ANIP’s profit will be $15.97M for 14.64 P/E if the $1.32 EPS becomes a reality. After $1.28 actual EPS reported by ANI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.13 % EPS growth.

More notable recent ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were published by: which released: “ANI Pharmaceuticals Q4 2018 Earnings Preview – Seeking Alpha” on February 26, 2019, also with their article: “ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: What You Should Know – Nasdaq” published on April 18, 2019, published: “ANI Pharmaceuticals (ANIP) Q2 Earnings Surpass Estimates – Nasdaq” on August 07, 2019. More interesting news about ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) were released by: and their article: “What’s in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings? – Nasdaq” published on April 30, 2019 as well as‘s news article titled: “ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know – Nasdaq” with publication date: April 12, 2019.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $934.99 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It has a 53.45 P/E ratio. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.